Seqster, a provider of interoperability to retrieve and harmonize electronic health records, genetic, and continuous monitoring data from distinct sources, secured investment from Takeda Pharmaceuticals, a Japanese biopharmaceutical company.
The company will use the new funds to accelerate the adoption of its interoperability technology for enhancing clinical trials, patient engagement, and outcomes.
“Our funding of Seqster is a cornerstone of our digital health strategy, and further enables us to serve our patient community by advancing the deployment of innovative technology solutions,” stated Bruce Meadows, Head of Investments at Takeda Digital Ventures. “Seqster’s technology is a very unique platform that addresses interoperability on not only a nationwide scale but also globally. Interoperability is one of the biggest barriers to applying precision medicine to clinical trials and patient engagement.”
The Seqster interoperability platform helps healthcare providers and payers on board their members by seamlessly integrating into any payer, provider, or clinical research enterprise. The platform currently connects users to over 3,000 healthcare providers and over 100,000 hospitals and clinics nationwide.
“We are thrilled to have Takeda Pharmaceuticals as a strategic investor sharing our vision and mission of putting patients at the center of all of their health data and making health data into medicine,” stated Ardy Arianpour, Seqster’s CEO and co-founder. “We have created a unique data-sharing environment that retrieves, parses, and harmonizes multi-dimensional data sets, thereby accelerating the entire drug development process with high fidelity data hosted within a HIPAA-compliant and HiTrust data schema. Seqster provides clinical trial participants a secure platform to consent and share their data with investigators and study personnel in real-time creating a longitudinal health record that facilitates patient clinical trial onboarding, monitoring, and post-trial follow-ups.”
In a similar deal recently, AirStrip Technologies, a developer of interoperability platform that unites clinicians and patients across geographic, technology, and workflow boundaries, raised $21.5 million in equity funding.